Xeltis today announced what it describes as “very promising” preliminary efficacy and safety results from one of the centres participating in the AXESS study—a first-in-human (FIH) clinical trial of its restorative haemodialysis access graft, Axess. The company has also reported that enrolment in the trial is now complete, with 20 patients having been successfully implanted […]
The post Xeltis presents “promising” first-in-human data on restorative haemodialysis access graft appeared first on Vascular News.